The DOI matches its Crossref record; 131 of the 133 references it cites were found in a registry or an index.
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Abstract
Depression and Alzheimer's disease (AD) are substantial public health concerns. In the past decades, a link between the 2 disease entities has received extensive acknowledgment, yet the complex nature of this relationship demands further clarification. Some evidence indicates that midlife depression may be an AD risk factor, while a chronic course of depression in late life may be a precursor to or symptom of dementia. Recently, multiple pathophysiological mechanisms have been proposed to underlie the bidirectional relationship between depression and AD, including genetic predisposition, immune dysregulation, accumulation of AD-related biomarkers (e.g., amyloid-β and tau), and alterations in brain structure. Accordingly, numerous therapeutic approaches, such as pharmacology treatments, psychotherapy, and lifestyle interventions, have been suggested as potential means of interfering with these pathways. However, the current literature on this topic remains fragmented and lacks a comprehensive review characterizing the association between depression and AD. In this review, we aim to address these gaps by providing an overview of the co-occurrence and temporal relationship between depression and AD, as well as exploring their underlying mechanisms. We also examine the current therapeutic regimens for depression and their implications for AD management and outline key challenges facing the field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Selective serotonin reuptake inhibitors (SSRIs) like citalopram and sertraline have shown modest efficacy,42,43”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [42]
Citations
Cites
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728
Social stress induces neurovascular pathology promoting depression
Menard, C., Pfau, M. L., Hodes, G. E., Kana, V., Wang, V. X., Bouchard, S., Takahashi, A., Flanigan, M. E., Aleyasin, H., LeClair, K. B., et al. (2017) · Nature Neuroscience · doi:10.1038/s41593-017-0010-3 · Cited by 1,028
Resting-state functional connectivity in major depressive disorder: A review
Mulders, P. C., van Eijndhoven, P. F., Schene, A. H., Beckmann, C. F., & Tendolkar, I. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.014 · Cited by 884
McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07757 · Cited by 800
The role of adult hippocampal neurogenesis in brain health and disease
Toda, T., Parylak, S. L., Linker, S. B., & Gage, F. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0036-2 · Cited by 719
Enache, D., Pariante, C. M., & Mondelli, V. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.015 · Cited by 615
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532
Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study
Singh-Manoux, A., Dugravot, A., Fournier, A., Abell, J., Ebmeier, K., Kivimäki, M., & Sabia, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0660 · Cited by 529
Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier
Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81108 · Cited by 477
Cited by
Sorted by citations
A 2025 update on treatment strategies for the Alzheimer’s disease spectrum
Wu, C.-K., & Fuh, J.-L. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001252 · Cited by 77
“43”
Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies
Wang, S., Liao, Z., Zhang, Q., Han, X., Liu, C., & Wang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1484373 · Cited by 67
Paradela, R. S., Calandri, I. L., Castro, N. P., Garat, E., Delgado, C., Crivelli, L., Yaffe, K. S., Ferri, C. P., Mukadam, N., Livingston, G., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00275-4 · Cited by 50
Mao, Y., Zhang, L., Zhang, C., Qin, L., Liao, X., & Zhao, L. (2025) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2025.127692 · Cited by 43
Yassin, L. K., Skrabulyte-Barbulescu, J., Alshamsi, S. H., Saeed, S., Alkuwaiti, S. H., Almazrouei, S., Alnuaimi, A., BaniYas, S., Aldhaheri, D., Alderei, M., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1667448 · Cited by 48
Metadata
- Authors
- Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Yu, Jin-Tai
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 95
- Issue
- 11
- Pages
- 992-1005
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W4387802230
- Cited by
- 164
- References
- 133
- Citations by year
- 2026: 63 · 2025: 83 · 2024: 18
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- depression, Alzheimer's disease, dementia, geriatric depression, bidirectional relationship, amyloid-beta, tau protein, immune dysregulation, genetic susceptibility, brain structure, pharmacotherapy, psychotherapy, lifestyle intervention, risk factors
- MeSH terms
- Alzheimer Disease, Antidepressive Agents, Depression, Depressive Disorder, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
